Although barasertib has been evaluated in combination with hypomethylating agents across multiple Phase 1–3 trials in AML (NCT00497991, NCT00926731, NCT00952588), these have not explicitly evaluated response in TP53 mutant AML [187,188,189]. This evidence concerns the gene TP53 and acute myeloid leukemia.